◆英語タイトル:Vectura Group Plc (VEC) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME7949PD
◆発行会社(調査会社):
GlobalData
◆発行日:2021年1月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Vectura Group Plc (Vectura) is a formulation, device design and development company. It focuses on the development of inhaled airways products through an integrated inhaled drug delivery platform. Its major products include dry powder inhalers (DPI) and metered dose inhalers (MDI) for patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other ailments. The company develops products based on proprietary lung delivery technologies. It has partnership and license agreements with global biotechnology and pharmaceutical companies to develop a portfolio of drugs, including inhaled in-market products and inhaled generics. Vectura is headquartered in Chippenham, Wiltshire, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vectura Group Plc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
List of Tables
List of Figures
Vectura Group Plc Company Overview
Vectura Group Plc Company Snapshot
Vectura Group Plc Pipeline Products and Ongoing Clinical Trials Overview
Vectura Group Plc – Pipeline Analysis Overview
Business Description
Vectura Group Plc – Key Facts
Vectura Group Plc – Major Products and Services
Vectura Group Plc Pipeline Products by Development Stage
Vectura Group Plc Ongoing Clinical Trials by Trial Status
Vectura Group Plc Pipeline Products Overview
Digitally – Connected LOMI Device
Digitally – Connected LOMI Device Product Overview
Flutiform pMDI
Flutiform pMDI Product Overview
Open-Inhale-Close Dry Powder Inhaler
Open-Inhale-Close Dry Powder Inhaler Product Overview
SKP-2075
SKP-2075 Product Overview
VR475 Combination Device
VR475 Combination Device Product Overview
VR647
VR647 Product Overview
VR647 Clinical Trial
Vectura Group Plc – Key Competitors
Vectura Group Plc – Key Employees
Vectura Group Plc – Key Employee Biographies
Vectura Group Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Vectura Group Plc, Recent Developments
Jan 12, 2021: Vectura Group: Trading update
Apr 17, 2020: Vectura presents latest science at Digital RDD 2020
Nov 27, 2019: VR315US: Hikma submits response to FDA
Oct 29, 2019: Vectura Group appoints New Chief Executive Officer
Oct 22, 2019: Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019
Oct 04, 2019: UK court dismisses GSK’s claims of passing off in respect of Sandoz’s AirFluSal Forspiro
Sep 26, 2019: Vectura Group: Board Change
Sep 13, 2019: Vectura provides update on GSK Litigation
Sep 10, 2019: Vectura delivers strong financial performance for H1 2019 and confirms proposed special dividend of approximately £40m in aggregate plus a £20m buyback programme
Sep 10, 2019: Vectura Group interim results for the six months ended 30 June 2019
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Vectura Group Plc Pipeline Products and Ongoing Clinical Trials Overview
Vectura Group Plc Pipeline Products by Equipment Type
Vectura Group Plc Pipeline Products by Indication
Vectura Group Plc Ongoing Clinical Trials by Trial Status
Vectura Group Plc, Key Facts
Vectura Group Plc, Major Products and Services
Vectura Group Plc Number of Pipeline Products by Development Stage
Vectura Group Plc Pipeline Products Summary by Development Stage
Vectura Group Plc Ongoing Clinical Trials by Trial Status
Vectura Group Plc Ongoing Clinical Trials Summary
Digitally - Connected LOMI Device - Product Status
Digitally - Connected LOMI Device - Product Description
Flutiform pMDI - Product Status
Flutiform pMDI - Product Description
Open-Inhale-Close Dry Powder Inhaler - Product Status
Open-Inhale-Close Dry Powder Inhaler - Product Description
SKP-2075 - Product Status
SKP-2075 - Product Description
VR475 Combination Device - Product Status
VR475 Combination Device - Product Description
VR647 - Product Status
VR647 - Product Description
VR647 - A Phase I Clinical Study of VR-647
VR647 - A Phase I Clinical Study of VR-647 in Adult Asthma Subjects
VR647 - Phase II Pharmacokinetic Study of VR-647 in Children
VR647 - Phase III Study of VR-647
Vectura Group Plc, Key Employees
Vectura Group Plc, Key Employee Biographies
Vectura Group Plc, Other Locations
Vectura Group Plc, Subsidiaries
Glossary